Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
The AMR Action Fund, established in 2020, is the world's largest venture capital fund focused on combating antimicrobial resistance (AMR). This fund was created through collaboration among prominent organizations, including the International Federation of Pharmaceutical Manufacturers and Associations, the World Health Organization, and the Wellcome Trust. The fund addresses a critical global health challenge, as AMR is responsible for approximately 1.3 million deaths annually.
Currently, the AMR Action Fund manages assets totaling $1 billion and has invested in 11 clinical-stage biotechnology companies. The fund's mission is to enable breakthroughs in antimicrobial therapies and ensure the development of new antibiotics to meet urgent health needs. The fund's unique positioning allows it to leverage a powerful network of over 20 leading pharmaceutical companies, enhancing the chances of success for its portfolio companies.
The AMR Action Fund primarily invests in small and mid-size biotechnology companies that are developing treatments for priority pathogens identified by the World Health Organization and the Centers for Disease Control and Prevention. The fund emphasizes clinical-stage investments, focusing on both traditional small-molecule antibiotics and innovative modalities such as bacteriophages and antibody treatments.
In addition to providing capital, the fund advocates for market reforms to enhance the value and accessibility of lifesaving drugs. The AMR Action Fund aims to launch 2-4 new antibiotics by 2030, bridging the market failure in antibiotic development with significant backing from major pharmaceutical companies.
The AMR Action Fund's portfolio includes 11 notable companies, each contributing to the fight against antimicrobial resistance:
Henry Skinner, PhD, MBE, MJur - Chief Executive Officer. Henry has extensive experience in the pharmaceutical industry and has held leadership roles in various biotech firms.
Martin Heidecker, PhD, MBA - Chief Investment Officer. Martin brings a wealth of knowledge in investment strategies and has a strong background in biotech investments.
Bill Burns - Board Chair. Bill has a notable history in the pharmaceutical sector, having led several successful companies.
David Hellmuth, JD - General Counsel, Chief Compliance Officer, Chief Operating Officer. David has a legal background with expertise in compliance and operational management.
John Vancura, MBA - Chief Financial Officer. John has significant experience in financial management within the biotech industry.
To pitch to the AMR Action Fund, founders should visit their contact page at amractionfund.com/contact. The pitch deck should include a clear overview of the technology, market opportunity, and team background. Response times may vary, so founders are encouraged to follow up if they do not receive a timely response.
As of March 2023, the AMR Action Fund continues to actively engage with the biotech community, promoting its mission to combat antimicrobial resistance. The fund is on track to launch 2-4 new antibiotics by 2030, reflecting its commitment to supporting clinical-stage companies in this critical area.
Q?
What are the investment criteria for the AMR Action Fund?
The AMR Action Fund invests in clinical-stage biotechnology companies focused on developing treatments for priority pathogens identified by the WHO and CDC.
Q?
How can founders apply or pitch to the AMR Action Fund?
Founders can submit their pitch through the AMR Action Fund's contact page at amractionfund.com/contact.
Q?
What makes the AMR Action Fund different from other venture capital firms?
The AMR Action Fund is unique in its exclusive focus on combating antimicrobial resistance and its backing from over 20 major pharmaceutical companies, providing unparalleled access to resources and networks.
Q?
What is the geographic scope of the AMR Action Fund?
The fund has a global investment focus, targeting biotechnology companies worldwide that are addressing antimicrobial resistance.
Q?
What is the typical check size for investments?
The AMR Action Fund invests in pre-seed, seed, and Series A stages, but specific check sizes are not disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.